- Pravadoline
- 4MeO-PH-MOEMIMO
- WIN 48,098
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Apr 2012. 401 kB.
Kneisel, S; Auwärter, V; Kempf, J. Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry Drug Test. Anal., 1 Aug 2013, 5 (8), 657-669. 285 kB. https://doi.org/10.1002/dta.1429
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #25
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report) Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #3. WIN 48,098
Wilkinson, SM; Banister, SD; Kassiou, M. Bioisosteric fluorine in the clandestine design of synthetic cannabinoids Aust. J. Chem., 10 Feb 2015, 68 (1), 4–8. 451 kB. https://doi.org/10.1071/CH14198 #6
Wouters, E; Walraed, J; Robertson, MJ; Meyrath, M; Szpakowska, M; Chevigné, A; Skiniotis, G; Stove, C. Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds ACS Pharmacol. Transl. Sci., 10 Apr 2020, 3 (2), 285–295. 2.0 MB. https://doi.org/10.1021/acsptsci.9b00069 #4
Eissenstat, MA; Bell, MR; D’Ambra, TE; Alexander, EJ; Daum, SJ; Ackerman, JH; Gruett, MD; Kumar, V; Estep, KG. Aminoalkylindoles: Structure-activity relationships of novel cannabinoid mimetics J. Med. Chem., 1 Aug 1995, 38 (16), 3094–3105. 3.0 MB. https://doi.org/10.1021/jm00016a013 #21 NMR,IR